Should I Buy Biontech BNTX Stock | Stocks To Buy Right Now | What is Biontech
Biontech BTNX is growing rapidly with the increase of vaccines needed, in this video I go over if this is still a great company to invest with.
WeBull Referral
https://act.webull.com/ni/f2BMuVEhEEu...
Stash Referral
https://get.stash.com/orlando1qt83
Cashapp Referral
https://cash.app/app/KGTQDWC
Referral link for Coinbase:
coinbase.com/join/carswe_z1?src=ios-link
Referral link for Gemini:
https://gemini.com/share/56rnvn83g
Referral link for Bittrex:
https://bittrex.com/Account/Register?...
Robinhood Referral: http://join.robinhood.com/orlandc30
OnlyFans
https://onlyfans.com/landosuccess
Investing 101:
https://vimeo.com/429182590
Investing Strategies:
https://vimeo.com/444076983
My Book: Against All Odds
https://www.amazon.com/dp/1732361401/...
Facebook Investors Group
https://www.facebook.com/groups/26634...
Recommended Books:
Can't Hurt Me: David Goggins
https://www.amazon.com/dp/B07KKP62FW?...
The Buffet Way
https://www.amazon.com/dp/B0006IU3NU/...
Rich Dad's Cashflow Quadrant
https://www.amazon.com/dp/1612680054/...
Secrets of the Millionaire Mind
https://www.amazon.com/dp/0060763280/...
Instagram:
https://www.instagram.com/landosucces...
Biontech
BioNTech SE short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.
In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which offers a 95% efficacy in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine. On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the UK. It was the first mRNA vaccine ever authorized. Some days later the vaccine also got an emergency approval in the United States, Canada, and Switzerland. On 21 December 2020, the European Commission approved BioNTech/Pfizer's coronavirus vaccine in accordance with the positive recommendation of the European Medicines Agency (EMA).
#BTNX #Biontech #BTNXStock
*links above include affiliate commissions of referrals. I'm part of an affiliate network and I receive compensation from partnering websites. The video is accurate as of the post date but may not be accurate in the future.